An Update on Temporomandibular Disorders (TMDs) and Headache

被引:7
作者
Romero-Reyes, Marcela [1 ,2 ]
Klasser, Gary [3 ]
Akerman, Simon [2 ]
机构
[1] Univ Maryland, Sch Dent, Brotman Facial Pain Clin, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Dent, Dept Pain & Neural Sci, 650 W Baltimore St, 8th floor, Baltimore, MD 21201 USA
[3] Louisiana State Univ, Sch Dent, Hlth Sci Ctr, Dept Diagnost Sci, New Orleans, LA USA
关键词
TMD; Orofacial pain; Headache; Migraine; Comorbidity; CGRP; CHRONIC PAIN CONDITIONS; TENSION-TYPE HEADACHE; OROFACIAL PAIN; DIAGNOSTIC-CRITERIA; ORAL APPLIANCES; SLEEP BRUXISM; MIGRAINE; SYMPTOMS; PREVALENCE; ASSOCIATION;
D O I
10.1007/s11910-023-01291-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of ReviewTo provide an overview and highlight recent updates in temporomandibular disorders (TMDs) and their comorbidity with headache disorders regarding pathophysiology and management.Recent FindingsIn the last decade, there have been great advancements in the understanding of TMDs and their relationship with neurovascular pains such as headaches. Understanding of TMDs is necessary for the context of its comorbidity with primary headache disorders. The literature regarding management of these comorbidities is scarce but points to combination therapy including pharmacological and non-pharmacological approaches to optimize management. The use of CGRP receptor-targeted monoclonal antibodies or CGRP receptor antagonists should be explored for the management of chronic TMDs. It could also be used as a novel monotherapy or in combination with non-pharmacological approaches for TMDs' comorbidity with headache, particularly migraine.Research is needed to support evidence-based management protocols. A team involving neurology (headache medicine) and dentistry (orofacial pain) is critical for optimal management.
引用
收藏
页码:561 / 570
页数:10
相关论文
共 105 条
  • [1] Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
    Ailani, Jessica
    Blumenfeld, Andrew M.
    [J]. HEADACHE, 2022, 62 (01): : 106 - 108
  • [2] The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
    Ailani, Jessica
    Burch, Rebecca C.
    Robbins, Matthew S.
    [J]. HEADACHE, 2021, 61 (07): : 1021 - 1039
  • [3] Ailani Jessica, 2021, Continuum (Minneap Minn), V27, P597, DOI 10.1212/CON.0000000000000956
  • [4] Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP
    Akerman, Simon
    Romero-Reyes, Marcela
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (24) : 5555 - 5568
  • [5] Cervical Muscle Tenderness in Temporomandibular Disorders and Its Associations with Diagnosis, Disease-Related Outcomes, and Comorbid Pain Conditions
    Almoznino, Galit
    Zini, Avraham
    Zakuto, Avraham
    Zlutzky, Hulio
    Bekker, Stav
    Shay, Boaz
    Haviv, Yaron
    Sharav, Yair
    Benoliel, Rafael
    [J]. JOURNAL OF ORAL & FACIAL PAIN AND HEADACHE, 2020, 34 (01) : 67 - 76
  • [6] American Academy of Orofacial Pain (AAOP), 2023, OR PAIN SPEC
  • [7] Prevalence of neck pain in migraine and tension-type headache: A population study
    Ashina, Sait
    Bendtsen, Lars
    Lyngberg, Ann C.
    Lipton, Richard B.
    Hajiyeva, Nazrin
    Jensen, Rigmor
    [J]. CEPHALALGIA, 2015, 35 (03) : 211 - 219
  • [8] Identification of clusters of individuals relevant to temporomandibular disorders and other chronic pain conditions: the OPPERA study
    Bair, Eric
    Gaynor, Sheila
    Slade, Gary D.
    Ohrbach, Richard
    Fillingim, Roger B.
    Greenspan, Joel D.
    Dubner, Ronald
    Smith, Shad B.
    Diatchenko, Luda
    Maixner, William
    [J]. PAIN, 2016, 157 (06) : 1266 - 1278
  • [9] Are headache and temporomandibular disorders related? A blinded study
    Ballegaard, V.
    Thede-Schmidt-Hansen, P.
    Svensson, P.
    Jensen, R.
    [J]. CEPHALALGIA, 2008, 28 (08) : 832 - 841
  • [10] Bartsch T., 2005, Headache Curr, V2, P42, DOI DOI 10.1111/J.1743-5013.2005.20201.X